ATE224194T1 - Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen - Google Patents

Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen

Info

Publication number: ATE224194T1
Authority: AT; Austria
Prior art keywords: xenotransplantations; treatment; vascular diseases; rapamycin derivative; rapamycin
Prior art date: 1996-03-27

Application number

AT97915441T

Other languages

English (en)

Inventor

Walter Schuler

Hendrik Schuurman

Gisbert Weckbecker

Hans-Guenter Zerwes

Original Assignee

Novartis Erfind Verwalt Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-27

Filing date

1997-03-26

Publication date

2002-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE224194(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-26 Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh

2002-10-15 Application granted granted Critical

2002-10-15 Publication of ATE224194T1 publication Critical patent/ATE224194T1/de

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
208000019553 vascular disease Diseases 0.000 title 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
208000024248 Vascular System injury Diseases 0.000 abstract 1
208000012339 Vascular injury Diseases 0.000 abstract 1
206010053648 Vascular occlusion Diseases 0.000 abstract 1
229960002170 azathioprine Drugs 0.000 abstract 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000000265 leukocyte Anatomy 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
229960000485 methotrexate Drugs 0.000 abstract 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 abstract 1
229960004866 mycophenolate mofetil Drugs 0.000 abstract 1
229960000951 mycophenolic acid Drugs 0.000 abstract 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
229960001967 tacrolimus Drugs 0.000 abstract 1
230000008719 thickening Effects 0.000 abstract 1
208000021331 vascular occlusion disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Transplantation (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT97915441T 1996-03-27 1997-03-26 Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen ATE224194T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9606452.2A GB9606452D0 (en)	1996-03-27	1996-03-27	Organic compounds
PCT/EP1997/001548 WO1997035575A1 (en)	1996-03-27	1997-03-26	Use of rapamycin derivatives in vasculopathies and xenotransplantation

Publications (1)

Publication Number	Publication Date
ATE224194T1 true ATE224194T1 (de)	2002-10-15

Family

ID=10791127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97915441T ATE224194T1 (de)	1996-03-27	1997-03-26	Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen

Country Status (29)

Country	Link
US (5)	US6384046B1 (de)
EP (3)	EP0893996B1 (de)
JP (2)	JP2000507226A (de)
KR (2)	KR100836971B1 (de)
CN (1)	CN1124135C (de)
AT (1)	ATE224194T1 (de)
AU (1)	AU716514B2 (de)
BR (1)	BR9708358A (de)
CA (1)	CA2247275C (de)
CY (1)	CY2404B1 (de)
CZ (1)	CZ292483B6 (de)
DE (1)	DE69715611T2 (de)
DK (2)	DK0893996T3 (de)
ES (2)	ES2184078T3 (de)
GB (1)	GB9606452D0 (de)
HU (1)	HU226422B1 (de)
ID (1)	ID17195A (de)
IL (1)	IL125812A (de)
MY (1)	MY117798A (de)
NO (1)	NO316667B1 (de)
NZ (1)	NZ331463A (de)
PL (1)	PL187732B1 (de)
PT (2)	PT2008657E (de)
RU (1)	RU2214247C2 (de)
SI (1)	SI2008657T1 (de)
SK (1)	SK284343B6 (de)
TR (1)	TR199801919T2 (de)
WO (1)	WO1997035575A1 (de)
ZA (1)	ZA972719B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
DE69736750T2 (de)	1996-07-30	2007-08-16	Novartis Ag	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6890546B2 (en)	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
WO2000067773A2 (en) *	1999-05-10	2000-11-16	Novartis Ag	Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US7807211B2 (en)	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US20070032853A1 (en) *	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en)	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US20070055367A1 (en) *	2000-03-15	2007-03-08	Orbus Medical Technologies, Inc.	Medical device with coating that promotes endothelial cell adherence and differentiation
US8460367B2 (en) *	2000-03-15	2013-06-11	Orbusneich Medical, Inc.	Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en)	2000-03-15	2012-01-03	Orbusneich Medical, Inc.	Progenitor endothelial cell capturing with a drug eluting implantable medical device
WO2001068158A1 (en)	2000-03-15	2001-09-20	Orbus Medical Technologies Inc.	Coating that promotes endothelial cell adherence
US20030229393A1 (en) *	2001-03-15	2003-12-11	Kutryk Michael J. B.	Medical device with coating that promotes cell adherence and differentiation
US9522217B2 (en)	2000-03-15	2016-12-20	Orbusneich Medical, Inc.	Medical device with coating for capturing genetically-altered cells and methods for using same
US20070141107A1 (en) *	2000-03-15	2007-06-21	Orbusneich Medical, Inc.	Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20050002986A1 (en) *	2000-05-12	2005-01-06	Robert Falotico	Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en)	2000-05-12	2007-11-27	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en)	2000-05-12	2012-08-07	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) *	2000-06-16	2002-01-31	American Home Products Corporation	Method of treating cardiovascular disease
US6670355B2 (en)	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
EP1709974A3 (de) *	2000-06-16	2006-12-06	Wyeth	Verfahren zur behandlung von kardiovaskulären erkrankungen mit rapamycin
WO2002026139A1 (en)	2000-09-29	2002-04-04	Cordis Corporation	Coated medical devices
CN1551767A (zh) *	2001-02-19	2004-12-01	��˹��ŵ��	癌症的治疗
US8741378B1 (en)	2001-06-27	2014-06-03	Advanced Cardiovascular Systems, Inc.	Methods of coating an implantable device
US6939376B2 (en)	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en)	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
WO2003070275A1 (en) *	2002-02-22	2003-08-28	Prophy Med Ab	Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) *	2002-04-24	2004-02-05	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
CN1655738A (zh) *	2002-05-20	2005-08-17	奥勃斯医学技术股份有限公司	可植入的药物洗脱医疗装置
US8109987B2 (en)	2003-04-14	2012-02-07	Tryton Medical, Inc.	Method of treating a lumenal bifurcation
US7279174B2 (en)	2003-05-08	2007-10-09	Advanced Cardiovascular Systems, Inc.	Stent coatings comprising hydrophilic additives
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
US7220755B2 (en)	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en)	2003-11-19	2015-08-25	Advanced Cardiovascular Systems, Inc.	Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005107817A2 (en) *	2004-04-30	2005-11-17	Orbus Medical Technologies, Inc.	Medical device with coating for capturing genetically-altered cells and methods of using same
EP1768662A2 (de)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Immunstimulatoren kleiner moleküle und assays für deren nachweis
US8709469B2 (en)	2004-06-30	2014-04-29	Abbott Cardiovascular Systems Inc.	Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en)	2004-09-24	2011-03-08	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US20060194829A1 (en) *	2004-12-20	2006-08-31	Clackson Timothy P	Therapeutic materials and methods
AU2006315512B2 (en)	2005-11-14	2012-11-01	Ariad Pharmaceuticals, Inc.	Administration of an mTOR inhibitor to treat patients with cancer
CN101340859B (zh) *	2005-11-17	2010-12-15	路嘉株式会社	用于制备在对身体的医疗手术中使用的插入物的方法
US20070173923A1 (en) *	2006-01-20	2007-07-26	Savage Douglas R	Drug reservoir stent
US7867988B2 (en)	2006-09-13	2011-01-11	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en)	2006-10-20	2008-04-24	Biosensors International Group	Drug-delivery endovascular stent and method of use
US8067055B2 (en) *	2006-10-20	2011-11-29	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method of use
US20080103584A1 (en) *	2006-10-25	2008-05-01	Biosensors International Group	Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) *	2007-09-19	2009-12-07	삼성전기주식회사	초광각 광학계
US8661630B2 (en)	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
CA2705764C (en)	2007-11-14	2016-08-02	Biosensors International Group, Ltd.	Automated stent coating apparatus and method
EP2245165A4 (de) *	2008-01-11	2011-06-01	Massachusetts Eye & Ear Infirm	Transgene konditionalstopp-dimerisierbare-caspase-tiere
EP2352459A4 (de) *	2008-10-03	2013-09-25	Elixir Medical Corp	Makrocyclische lactonverbindungen und verfahren zu ihrer verwendung
US8366763B2 (en)	2009-07-02	2013-02-05	Tryton Medical, Inc.	Ostium support for treating vascular bifurcations
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
UA104738C2 (ru)	2011-05-18	2014-03-11	Олег Миколайович Лазаренко	Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) *	2011-08-30	2013-08-28	成都摩尔生物医药有限公司	一种依维莫司的合成方法
US10682415B2 (en)	2013-07-22	2020-06-16	Wisconsin Alumni Research Foundation	Thermogel formulation for combination drug delivery
KR101723265B1 (ko)	2013-08-16	2017-04-04	가톨릭대학교 산학협력단	mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
CA3059017C (en)	2013-09-24	2021-05-25	Giner Life Sciences, Inc.	System for gas treatment of a cell implant
CN106061482A (zh)	2013-10-08	2016-10-26	拉姆医疗公司	用于治疗淋巴管平滑肌瘤病的雷帕霉素
RU2016136348A (ru)	2014-02-11	2018-03-16	Лэм Терапьютикс, Инк.	Рапамицин для лечения лимфангиолейомиоматоза
US10307371B2 (en)	2014-02-11	2019-06-04	AI Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
NZ724756A (en)	2014-04-04	2023-07-28	Ai Therapeutics Inc	An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en)	2014-10-07	2023-02-21	Lam Therapeutics, Inc.	An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr)	2014-11-07	2017-09-12	Civitas Therapeutics Inc	Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en)	2015-02-10	2016-08-18	Lam Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
US20190167649A1 (en)	2016-08-10	2019-06-06	The Board Of Regents Of The University Of Texas System	Topical rapamycin therapy
CN109715224B (zh)	2016-09-19	2022-02-22	百多力股份公司	无聚合物的药物洗脱血管支架
JP6993003B2 (ja)	2016-11-15	2022-01-13	ガイナーライフサイエンシズ，インク．	皮下インプラントとの使用に適した経皮的ガス拡散装置
US11826492B2 (en)	2016-12-22	2023-11-28	Biotronik Ag	Intratumoral drug delivery materials and methods for treating breast cancer
EP3618916A4 (de)	2017-05-04	2021-04-14	Giner Life Sciences, Inc.	Robuste implantierbare gasabgabevorrichtung und verfahren, systeme und vorrichtungen damit
UY37900A (es)	2017-09-26	2019-04-30	Novartis Ag	Nuevos derivados de rapamicina
LT3898637T (lt)	2018-12-18	2025-03-10	Novartis Ag	Rapamicino dariniai
AU2020226527A1 (en)	2019-02-20	2021-10-14	AI Therapeutics, Inc.	Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
KR20260115158A (ko)	2019-03-26	2026-07-23	노파르티스 아게	이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en) *	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
US5364612A (en) *	1991-05-06	1994-11-15	Immunomedics, Inc.	Detection of cardiovascular lesions
ZA924953B (en) *	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
CA2086642C (en) *	1992-01-09	2004-06-15	Randall E. Morris	Method of treating hyperproliferative vascular disease
CA2094858C (en) *	1992-04-28	2004-06-15	Robert D. Mitchell	Method of treating hyperproliferative vascular disease
US5747034A (en) *	1992-07-09	1998-05-05	Chiron Corporation	Methods and materials for the induction of T cell anergy
US5283257A (en) *	1992-07-10	1994-02-01	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating hyperproliferative vascular disease
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
BR9408323A (pt) *	1993-12-17	1997-08-19	Sandoz Ag	Derivados de rapamicina
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US6265427B1 (en) *	1995-06-07	2001-07-24	The Proctor & Gamble Company	Pharmaceutical composition for the method of treating leukemia
DE69624921T2 (de) *	1995-06-09	2003-09-11	Novartis Ag, Basel	Rapamycinderivate
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds

1996
- 1996-03-27 GB GBGB9606452.2A patent/GB9606452D0/en active Pending
1997
- 1997-03-25 MY MYPI97001258A patent/MY117798A/en unknown
- 1997-03-25 ID IDP970980A patent/ID17195A/id unknown
- 1997-03-26 DK DK97915441T patent/DK0893996T3/da active
- 1997-03-26 HU HU0001267A patent/HU226422B1/hu unknown
- 1997-03-26 CA CA2247275A patent/CA2247275C/en not_active Expired - Lifetime
- 1997-03-26 KR KR1020057005463A patent/KR100836971B1/ko not_active Expired - Lifetime
- 1997-03-26 ES ES97915441T patent/ES2184078T3/es not_active Expired - Lifetime
- 1997-03-26 KR KR1020077008212A patent/KR20070083654A/ko not_active Withdrawn
- 1997-03-26 WO PCT/EP1997/001548 patent/WO1997035575A1/en not_active Ceased
- 1997-03-26 DK DK08017336.2T patent/DK2008657T3/da active
- 1997-03-26 EP EP97915441A patent/EP0893996B1/de not_active Revoked
- 1997-03-26 EP EP08017336.2A patent/EP2008657B1/de not_active Expired - Lifetime
- 1997-03-26 PT PT80173362T patent/PT2008657E/pt unknown
- 1997-03-26 AU AU22918/97A patent/AU716514B2/en not_active Expired
- 1997-03-26 CN CN97193278A patent/CN1124135C/zh not_active Expired - Lifetime
- 1997-03-26 NZ NZ331463A patent/NZ331463A/en not_active IP Right Cessation
- 1997-03-26 BR BR9708358A patent/BR9708358A/pt not_active Application Discontinuation
- 1997-03-26 IL IL12581297A patent/IL125812A/en not_active IP Right Cessation
- 1997-03-26 RU RU98119312/14A patent/RU2214247C2/ru active
- 1997-03-26 PT PT97915441T patent/PT893996E/pt unknown
- 1997-03-26 PL PL97328659A patent/PL187732B1/pl unknown
- 1997-03-26 SK SK1327-98A patent/SK284343B6/sk not_active IP Right Cessation
- 1997-03-26 SI SI9730801T patent/SI2008657T1/sl unknown
- 1997-03-26 TR TR1998/01919T patent/TR199801919T2/xx unknown
- 1997-03-26 AT AT97915441T patent/ATE224194T1/de not_active IP Right Cessation
- 1997-03-26 ES ES08017336T patent/ES2421455T3/es not_active Expired - Lifetime
- 1997-03-26 JP JP9532077A patent/JP2000507226A/ja not_active Withdrawn
- 1997-03-26 EP EP01116262A patent/EP1149581A3/de not_active Withdrawn
- 1997-03-26 CZ CZ19983070A patent/CZ292483B6/cs not_active IP Right Cessation
- 1997-03-26 DE DE69715611T patent/DE69715611T2/de not_active Revoked
- 1997-03-27 ZA ZA972719A patent/ZA972719B/xx unknown
1998
- 1998-09-18 NO NO19984340A patent/NO316667B1/no not_active IP Right Cessation
2000
- 2000-11-14 US US09/712,359 patent/US6384046B1/en not_active Expired - Lifetime
2002
- 2002-03-07 US US10/092,639 patent/US20020127248A1/en not_active Abandoned
2004
- 2004-01-08 CY CY0400004A patent/CY2404B1/xx unknown
2008
- 2008-12-10 JP JP2008314494A patent/JP5124431B2/ja not_active Expired - Lifetime
2010
- 2010-03-01 US US12/715,007 patent/US20100152105A1/en not_active Abandoned
2012
- 2012-01-24 US US13/357,199 patent/US20120177690A1/en not_active Abandoned
2014
- 2014-03-05 US US14/197,368 patent/US20140187574A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK0893996T3 (da)	2002-12-09
SK284343B6 (sk)	2005-02-04
DK2008657T3 (da)	2013-07-22
NZ331463A (en)	2001-10-26
EP2008657B1 (de)	2013-04-24
EP0893996B1 (de)	2002-09-18
KR20050038656A (ko)	2005-04-27
MY117798A (en)	2004-08-30
PT2008657E (pt)	2013-07-12
CY2404B1 (en)	2004-09-10
IL125812A0 (en)	1999-04-11
HUP0001267A2 (hu)	2000-11-28
WO1997035575A1 (en)	1997-10-02
ID17195A (id)	1997-12-11
HK1018688A1 (en)	1999-12-30
CN1124135C (zh)	2003-10-15
PL187732B1 (pl)	2004-09-30
SI2008657T1 (sl)	2013-07-31
AU716514B2 (en)	2000-02-24
NO316667B1 (no)	2004-03-29
NO984340L (no)	1998-09-18
GB9606452D0 (en)	1996-06-05
JP2000507226A (ja)	2000-06-13
CZ307098A3 (cs)	1999-01-13
US20140187574A1 (en)	2014-07-03
BR9708358A (pt)	1999-08-03
ZA972719B (en)	1998-09-28
EP2008657A3 (de)	2009-02-04
US20120177690A1 (en)	2012-07-12
CA2247275A1 (en)	1997-10-02
US20020127248A1 (en)	2002-09-12
JP5124431B2 (ja)	2013-01-23
ES2421455T3 (es)	2013-09-02
EP1149581A3 (de)	2003-12-03
SK132798A3 (en)	1999-03-12
US6384046B1 (en)	2002-05-07
JP2009102349A (ja)	2009-05-14
EP2008657A2 (de)	2008-12-31
ES2184078T3 (es)	2003-04-01
EP0893996A1 (de)	1999-02-03
US20100152105A1 (en)	2010-06-17
PL328659A1 (en)	1999-02-15
KR100836971B1 (ko)	2008-06-10
HU226422B1 (en)	2008-12-29
KR20070083654A (ko)	2007-08-24
NO984340D0 (no)	1998-09-18
EP1149581A2 (de)	2001-10-31
DE69715611D1 (de)	2002-10-24
PT893996E (pt)	2002-12-31
HUP0001267A3 (en)	2002-01-28
AU2291897A (en)	1997-10-17
CN1214631A (zh)	1999-04-21
DE69715611T2 (de)	2003-05-22
TR199801919T2 (xx)	1999-02-22
CZ292483B6 (cs)	2003-09-17
CA2247275C (en)	2011-10-11
RU2214247C2 (ru)	2003-10-20
IL125812A (en)	2001-12-23

Legal Events

Date

Code

Title

Description

2003-07-15

UEP

Publication of translation of european patent specification

Ref document number: 0893996

Country of ref document: EP

2008-12-15

RZN

Patent revoked

Publication	Publication Date	Title
DE69715611D1 (de)	2002-10-24	Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen
EA200401070A1 (ru)	2005-02-24	Способы лечения сосудистых заболеваний
DE69524679D1 (de)	2002-01-31	Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE69633717D1 (de)	2004-12-02	Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE69328981D1 (de)	2000-08-17	Verfahren zur Behandlung von hyperproliferaktiven Gefässerkrankungen unter Verwendung von Rapamycin, eventuell in Kombination mit Mykophenolsäure
TW249198B (en)	1995-06-11	Stents for autologous tissue heart valve
EP0792156A4 (de)	2000-03-01	Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit
DE69527847D1 (de)	2002-09-26	Verwendung von anti-vegf-mitteln zur behandlung der endometriose
EA200000848A1 (ru)	2001-04-23	Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
BR9506820A (pt)	1997-09-09	Derivados de 4-amino de ácido micofenólico
ATE400301T1 (de)	2008-07-15	Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen
DE69435303D1 (de)	2010-09-02	Er behandlung von krankheiten bei denen eine cytok
DE69738522D1 (de)	2008-04-03	Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
DE69519937D1 (de)	2001-02-22	Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE69819911D1 (de)	2003-12-24	88kda tumorgener wachstumsfaktor und antagonisten
DE69129460D1 (de)	1998-06-25	Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
ATE356995T1 (de)	2007-04-15	Verfahren zur identifizierung von mitteln zur behandlung von diabetes
EP1499190A4 (de)	2005-06-15	Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
ATE343398T1 (de)	2006-11-15	Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE69522564D1 (de)	2001-10-11	Alkalibeständiges proteinadsorbens
DE60015791D1 (de)	2004-12-16	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
EA199901061A1 (ru)	2000-06-26	Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
EP1363528A4 (de)	2006-09-27	Verfahren zur diagnose und behandlung von herzerkrankungen
DK0745072T3 (da)	1999-01-18	4-aminoderivater af 5-substitueret mycophenolsyre
DE60228945D1 (de)	2008-10-30	Verwendung von cd25-bindender moleküle für patienten mit steroide-resistenz